CRVS

Corvus Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

7.600

-0.22(-2.813%)1D

Line

Candle

YTD

High

7.780

Open

7.690

VWAP

7.35

Vol

946.63K

Mkt Cap

567.58M

Low

7.0101

Amount

6.96M

EV/EBITDA(TTM)

Total Shares

62.55M

501.89M

EV/OCF(TTM)

P/S(TTM)

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q1

FY2025Q4

-0.134

+33.5%

-0.137

-167.63%

-0.129

-28.09%

Estimates Revision

The market is revising No Change the revenue expectations for Corvus Pharmaceuticals, Inc. (CRVS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 73.91%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+20.75%

In Past 3 Month

Stock Price

Go Up

+73.91%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast CRVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRVS is 13.75 USD with a low forecast of 11.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 7.600

Low

11.00

Averages

13.75

High

16.00

Current: 7.600

Low

11.00

Averages

13.75

High

16.00

Mizuho

Outperform

maintain

$11 -> $13

2025-10-29

Reason

Mizuho

Price Target

$11 -> $13

2025-10-29

maintain

Outperform

Reason

Mizuho raised the firm's price target on Corvus Pharmaceuticals to $13 from $11 and keeps an Outperform rating on the shares.

Oppenheimer

Jeff Jones

Outperform

downgrade

$17 -> $15

2025-08-08

Reason

Oppenheimer

Jeff Jones

Price Target

$17 -> $15

2025-08-08

downgrade

Outperform

Reason

Oppenheimer analyst Jeff Jones lowered the firm's price target on Corvus Pharmaceuticals to $15 from $17 and keeps an Outperform rating on the shares. The firm notes the company reported Q2 results and provided an update on plans for soquelitnib across multiple indications. Oppenheimer models a $100M financing in 2026 to extend runway with model refinements.

Mizuho

Graig Suvannavejh

Outperform

downgrade

$12 -> $11

2025-05-20

Reason

Mizuho

Graig Suvannavejh

Price Target

$12 -> $11

2025-05-20

downgrade

Outperform

Reason

Oppenheimer

Outperform

maintain

$15 -> $17

2025-05-09

Reason

Oppenheimer

Price Target

$15 -> $17

2025-05-09

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Corvus Pharmaceuticals to $17 from $15 and keeps an Outperform rating on the shares. The firm notes that on Thursday afternoon, the company provided a Q1 business update alongside an in-depth review of their Phase 1 data for soquelitnib in AD, ahead of presentations at SID during the coming days. The AD update continues to support Oppenheimer's enthusiasm for the candidate in this potential blockbuster indication with EASI 75 responses achieved in 63% of Cohort 3 patients, while consistently seeing earlier, deeper, and non-plateauing responses through 28 days of dosing. The firm views these data as highly competitive with dupilimab and other systemic options for patients with AD.

HC Wainwright & Co.

Sean Lee

Strong Buy

Reiterates

$11

2025-03-26

Reason

HC Wainwright & Co.

Sean Lee

Price Target

$11

2025-03-26

Reiterates

Strong Buy

Reason

Oppenheimer

Jeff Jones

Buy

Maintains

$14 → $15

2025-03-26

Reason

Oppenheimer

Jeff Jones

Price Target

$14 → $15

2025-03-26

Maintains

Buy

Reason

Oppenheimer raised the firm's price target on Corvus Pharmaceuticals to $15 from $14 and keeps an Outperform rating on the shares after the company released year-end results and provided a business update. Clinical studies for soquelitinib are on track with updated Phase 1 data in AD anticipated at the Society for Investigative Dermatology in May. An update was just presented at the T Cell Lymphoma Forum last week, which provided longer-term follow for patients in the Phase 1b study, the firm says. Oppenheimer believes year-end cash of $52M remains a concern, with this amount insufficient to complete the ongoing Phase 3 study.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Corvus Pharmaceuticals Inc (CRVS.O) is -13.96, compared to its 5-year average forward P/E of -4.86. For a more detailed relative valuation and DCF analysis to assess Corvus Pharmaceuticals Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.86

Current PE

-13.96

Overvalued PE

-0.95

Undervalued PE

-8.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.69

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.39

Undervalued EV/EBITDA

-2.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

55.62

Current PS

7.60

Overvalued PS

224.11

Undervalued PS

-112.86